85 results
8-K
EX-99.1
GTHX
G1 Therapeutics Inc
1 May 24
Results of Operations and Financial Condition
6:38am
regimen for extensive-stage small cell lung cancer. Important Safety Information COSELA is contraindicated in patients with a history of serious
PRE 14A
GTHX
G1 Therapeutics Inc
12 Apr 24
Preliminary proxy
4:12pm
the environment and our communities. Health, safety, and environmental responsibilities are fundamental to our values. We aim to minimize our environmental impact … by conserving natural resources and reducing waste. Our company-wide sustainability initiatives include:
compliance with all applicable health, safety
8-K
EX-99.1
n6rvqw 5onoif0q0
28 Feb 24
Results of Operations and Financial Condition
6:35am
8-K
EX-99.1
xcqm bg2krw
12 Feb 24
Other Events
4:19pm
8-K
EX-99.1
bgugco vk
8 Jan 24
Results of Operations and Financial Condition
6:30am
8-K
EX-99.1
zbxgx7m
1 Nov 23
Results of Operations and Financial Condition
6:46am
8-K
EX-99.1
gefy3 ykq9oh
2 Aug 23
Results of Operations and Financial Condition
6:50am
8-K
EX-99.1
5hkp49k
3 May 23
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
6:46am
8-K
EX-1.1
gcgqs91 y4j
18 Nov 22
G1 Therapeutics Announces Pricing of Offering of Common Stock
8:00pm
424B5
w9s0hn9 a4hgsdb
18 Nov 22
Prospectus supplement for primary offering
7:37pm
424B5
2cyl6 8p4bcr
17 Nov 22
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.2
kc4i38pfb6xhirp5kuk
2 Nov 22
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
6:45am